Moderna has filed for marketing authorization in the U.S., EU, Canada and Australia for mRNA-1010 CAMBRIDGE, MA / ACCESS Newswire / January 5, 2026 / Moderna, Inc. (NASDAQ:MRNA) today provided an ...

The company submitted an application for a seasonal flu vaccine it believes to be a key growth driver in the years ahead.

Moderna (MRNA) has been quietly grinding higher, with the stock up roughly 11% over the past month and 12% in the past 3 ...

Bayer's Monsanto sued COVID-19 vaccine makers Pfizer , BioNTech and Moderna in Delaware federal court on Tuesday for allegedly misusing its messenger RNA technology in manufacturing their vaccines, a ...

Bayer has filed patent infringement lawsuits against COVID-19 vaccine makers Pfizer, BioNTech, Moderna, and Johnson & Johnson ...

Moderna, Inc. has rallied ~23%, but rated a Sell due to deteriorating fundamentals. Learn more about MRNA stock here.

This stock is a great choice for cautious and aggressive investors.

Bayer's Monsanto has sued Pfizer, BioNTech and Moderna, for allegedly misusing its messenger RNA technology in COVID vaccines ...

Wall Street saw record highs on Tuesday driven by a rally in AI-charged chip stocks and a price boost for Moderna. The Dow ...

Moderna will get up to $54.3 million in funding from a global coalition to support late-stage development of its experimental bird flu vaccine, the U.S. drugmaker said on Thursday.

Both vaccines work. But Pfizer requires a longer waiting period before the vaccine kicks in, while Moderna has stronger side effects.

Moderna (MRNA) provided an update on regulatory submissions for its investigational seasonal influenza vaccine, mRNA-1010, for adults aged 50 ...